The US Food and Drug Administration (FDA) has approved Sunharbo (asundexian), a new blood-thinning medicine developed by German pharmaceutical company Bayer, to reduce the risk of another stroke in certain high-risk adults. Announced on November 9, 2026, the approval introduces the first medicine targeting a clotting protein called Factor XIa (FXIa) for secondary stroke prevention in the United States. The once-daily tablet is designed for adults who have recently experienced a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA), commonly called a mini-stroke.
The approval is based on results from the Phase 3 OCEANIC-STROKE clinical trial, which enrolled 12,327 participants. Researchers found that Sunharbo reduced the risk of another ischemic stroke by 26% compared with placebo when both were used alongside antiplatelet therapy. Importantly, the overall rate of major bleeding was similar between the two groups, although gastrointestinal bleeding occurred more frequently among patients receiving Sunharbo. The approval could introduce a new treatment option for stroke survivors while opening a potentially important commercial opportunity for Bayer.
Key Takeaways
- The FDA approved Bayer’s Sunharbo (asundexian) on November 9, 2026.
- It is the first approved Factor XIa inhibitor in the United States.
- The medicine is designed to reduce repeat stroke risk in certain adults following an ischemic stroke or high-risk TIA.
- The recommended dose is 50 mg once daily alongside antiplatelet therapy.
- The Phase 3 trial included 12,327 participants.
- Sunharbo reduced recurrent ischemic stroke risk by 26% compared with placebo.
- Stroke occurred in 6.2% of the Sunharbo group versus 8.4% of the placebo group.
- Overall major bleeding rates were similar, but gastrointestinal bleeding was more frequent with Sunharbo.
- The medicine is not approved for stroke prevention in people with atrial fibrillation.
- Bayer sees Sunharbo as an important future growth product as its older blockbuster medicine Xarelto faces generic competition.
FDA Approves Sunharbo for Secondary Stroke Prevention
Sunharbo is the brand name for asundexian, an oral medication developed by Bayer.
The FDA approved the 50 mg tablet for use alongside antiplatelet therapy in adults who have recently experienced either:
- A mild-to-moderate non-cardioembolic ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of 15 or lower.
- A high-risk transient ischemic attack (TIA).
A non-cardioembolic ischemic stroke occurs when a blood clot blocks an artery supplying the brain, without the clot originating in the heart.
A transient ischemic attack occurs when blood flow to part of the brain is temporarily interrupted. Symptoms can resemble those of a stroke but resolve without the same persistent neurological injury. A high-risk TIA can indicate an increased risk of a subsequent stroke.
The treatment is intended for secondary prevention, which means reducing the likelihood of another stroke after a person has already experienced an initial event.
According to the FDA, patients in the pivotal clinical trial began treatment within 72 hours of their initial symptoms.
The recommended Sunharbo dose is 50 mg once daily, in combination with antiplatelet therapy.
How Does Sunharbo Work?
Sunharbo works differently from several widely used blood-thinning medications.
It inhibits Factor XIa, a protein involved in the body’s blood-clotting process.
When a blood vessel is damaged, the body activates a complex series of reactions that help form a clot and prevent excessive bleeding.
However, abnormal clot formation can also block blood vessels and cause serious medical problems, including ischemic strokes.
Sunharbo targets Factor XIa to reduce the amplification of clot formation.
How Factor XIa inhibition differs from existing blood thinners
Many established anticoagulant medicines target a different protein called Factor Xa.
For example, Eliquis (apixaban) and Xarelto (rivaroxaban) work by inhibiting Factor Xa, which plays an important role in the production of thrombin, a protein involved in clot formation.
Asundexian takes a different approach by targeting Factor XIa.
The scientific rationale is that Factor XIa inhibition may reduce harmful clot formation while having a comparatively smaller effect on the body’s normal ability to stop bleeding.
This does not mean that Sunharbo is free from bleeding risks. The FDA’s clinical-trial findings confirm that gastrointestinal bleeding was more common in patients receiving the drug.
| Medication or class | Main target | General function |
|---|---|---|
| Sunharbo (asundexian) | Factor XIa | Reduces amplification of clot formation |
| Eliquis (apixaban) | Factor Xa | Reduces thrombin generation |
| Xarelto (rivaroxaban) | Factor Xa | Reduces thrombin generation |
The introduction of a Factor XIa inhibitor represents a new approach to preventing recurrent ischemic strokes.
Phase 3 Trial Shows a 26% Reduction in Repeat Stroke Risk
The FDA’s approval was based on the OCEANIC-STROKE clinical trial, a large international Phase 3 study.
The trial enrolled 12,327 adults who had recently experienced a non-cardioembolic ischemic stroke or a high-risk TIA.
Participants were randomly assigned to receive either Sunharbo or a placebo. Both groups also received antiplatelet therapy.
The primary objective was to determine whether adding asundexian could reduce the risk of another ischemic stroke.
The results showed a statistically significant reduction.
Main clinical trial results
| Trial measurement | Sunharbo group | Placebo group |
|---|---|---|
| Number of participants | 6,162 | 6,165 |
| Patients experiencing ischemic stroke | 6.2% | 8.4% |
| Relative reduction in stroke risk | 26% | Reference group |
| Median treatment period | 14.2 months | 14.2 months |
The difference between the two groups was approximately 2.2 percentage points.
This means that approximately 22 fewer participants experienced an ischemic stroke per 1,000 treated participants over the trial’s observation period, based on the reported event proportions.
The 26% figure represents a relative reduction, not a 26-percentage-point reduction in absolute risk.
The trial provides evidence that adding Sunharbo to antiplatelet therapy can reduce recurrent ischemic strokes in the specific population studied.
However, the results should not automatically be applied to every stroke survivor. The approved indication is limited to the patient groups specified by the FDA.
Does Sunharbo Reduce Bleeding Risk?
One of the most important aspects of the OCEANIC-STROKE results was the comparison of bleeding events.
Traditional anticoagulant treatments can increase bleeding risk because they interfere with the body’s clotting mechanisms.
Researchers have been investigating whether Factor XIa inhibitors can reduce abnormal clot formation while preserving more of the body’s normal protective clotting activity.
In the OCEANIC-STROKE trial, the overall rate of major bleeding was similar between the Sunharbo and placebo groups.
However, the findings included several important safety details:
- Gastrointestinal bleeding occurred more frequently with Sunharbo.
- Major bleeding increased among participants older than 75 years.
- Major bleeding was also increased during the first 90 days of treatment.
- Diarrhoea was the most frequently reported adverse reaction, occurring in at least 3% of Sunharbo-treated patients.
Therefore, the approval should not be interpreted as evidence that Sunharbo eliminates bleeding risk.
The FDA’s conclusion was that the overall major bleeding rate was similar between the trial groups, not that every category of bleeding was unaffected.
Who Can Take Sunharbo?
The FDA approval is specifically intended for adults with recent non-cardioembolic ischemic stroke or high-risk TIA.
The drug is not approved for every type of stroke or for all people who need blood-thinning treatment.
Important restrictions include:
Atrial fibrillation: Sunharbo is not approved for stroke prevention in patients with atrial fibrillation.
Liver impairment: The medicine is not recommended for patients with moderate or severe hepatic impairment.
Drug interactions: Combining Sunharbo with medicines that are both P-glycoprotein and strong CYP3A4 inducers, such as carbamazepine, is not recommended because they may reduce its effectiveness.
Surgery and procedures: The FDA says Sunharbo should be withheld for at least 24 hours before elective surgery or invasive procedures.
Thrombolysis: It should also be withheld for at least 24 hours after thrombolysis for acute ischemic stroke.
The medicine must be used under medical supervision, particularly because patients recovering from a stroke may already be taking other medications that affect blood clotting.
Why Sunharbo Matters for Bayer
The approval represents an important development for Bayer’s pharmaceutical business.
The German company has been looking for new growth products as its established blockbuster medicine Xarelto faces competition from lower-cost generic versions following patent expiry.
Xarelto is an anticoagulant widely used to prevent and treat blood clots in certain patient groups.
Its patent-related loss of exclusivity has created pressure on Bayer to develop and commercialise new medicines capable of generating substantial revenue.
Sunharbo could become one of those products.
Bayer has previously described asundexian as a potential blockbuster medicine, a pharmaceutical industry term generally used for a drug capable of generating at least $1 billion in annual sales.
The company believes the treatment could address an important unmet need among people at risk of another stroke.
However, commercial success will depend on factors including prescribing guidelines, physician adoption, reimbursement, pricing and competition from other treatments.
Sunharbo Could Shape the Future of Blood-Thinning Medicines
The approval is also significant for the wider pharmaceutical industry because it introduces a new class of approved anticoagulant medicine for this indication.
Several pharmaceutical companies are investigating Factor XI and Factor XIa as potential targets for reducing harmful clot formation.
These include:
- Bayer: Developing asundexian, marketed as Sunharbo.
- Novartis: Developing abelacimab, a Factor XI-targeting antibody.
- Bristol Myers Squibb and Johnson & Johnson: Working together on milvexian, another Factor XIa inhibitor.
These medicines are at different stages of clinical development and are not interchangeable.
Sunharbo’s FDA approval gives Bayer an important position in the emerging market for Factor XIa-targeting treatments.
The next stage will involve monitoring real-world safety, effectiveness and patient outcomes after the drug becomes available.
The Bigger Picture
Sunharbo’s approval represents a new direction in stroke prevention because it targets Factor XIa rather than Factor Xa, the target of several established anticoagulants. The Phase 3 results showed a meaningful reduction in recurrent ischemic strokes without an overall increase in major bleeding compared with placebo, although gastrointestinal bleeding and certain higher-risk patient groups require particular attention.
For Bayer, the approval provides a new commercial opportunity as competition affects its older blood-thinning products. For the pharmaceutical industry, it could open the door to a broader generation of clot-prevention medicines designed to balance protection against dangerous blood clots with the body’s need for normal clotting. Whether this approach delivers lasting benefits will become clearer as physicians gain experience with the treatment.
Frequently Asked Questions
1. What is Sunharbo?
Sunharbo is the brand name for asundexian, an oral blood-thinning medicine developed by Bayer. It inhibits Factor XIa, a protein involved in blood clot formation.
2. What did the FDA approve Sunharbo for?
The FDA approved it to reduce the risk of another stroke in adults following a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, when used alongside antiplatelet therapy.
3. How much does Sunharbo reduce repeat stroke risk?
In the Phase 3 OCEANIC-STROKE trial, Sunharbo reduced recurrent ischemic stroke risk by 26% compared with placebo. Stroke occurred in 6.2% of the Sunharbo group and 8.4% of the placebo group.
4. Does Sunharbo increase bleeding risk?
The overall rate of major bleeding was similar between the Sunharbo and placebo groups. However, gastrointestinal bleeding was more frequent with Sunharbo, and major bleeding increased among patients older than 75 years and during the first 90 days of treatment.
5. What is the recommended Sunharbo dosage?
The FDA-approved dosage is 50 mg once daily, alongside antiplatelet therapy, for the specific patient population covered by the approval.
6. Is Sunharbo the same as Eliquis or Xarelto?
No. Sunharbo inhibits Factor XIa, while Eliquis and Xarelto inhibit Factor Xa. They have different mechanisms and approved uses.
7. Can people with atrial fibrillation take Sunharbo to prevent stroke?
Sunharbo is not approved for stroke prevention in patients with atrial fibrillation. Its approved indication is for certain patients following non-cardioembolic ischemic stroke or high-risk TIA.
8. Is Sunharbo available in India?
The November 9, 2026 announcement confirms US FDA approval. It does not establish approval or commercial availability in India. Indian regulatory authorisation would be a separate process.
Looking Ahead
Bayer will now focus on bringing Sunharbo into the US market and establishing its position among treatments used for secondary stroke prevention. The clinical results provide an important foundation, but physicians will closely monitor bleeding risks, patient selection and long-term outcomes as real-world use increases. The drug’s ability to deliver consistent benefits outside controlled clinical trials will be an important factor in determining its adoption.
For the wider pharmaceutical industry, the approval could encourage additional investment in Factor XIa-targeting medicines. If future research confirms that these drugs can prevent harmful clots while maintaining an acceptable bleeding profile, they could become an important addition to cardiovascular treatment. Sunharbo is an early milestone in that development, but further clinical evidence will determine how broadly the approach can be used.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
